The Lancet Infectious Diseases, Early Online Publication, 19 March 2013
doi:10.1016/S1473-3099(13)70046-X
AS03-adjuvanted versus non-adjuvanted
...
doi:10.1016/S1473-3099(13)70046-X
AS03-adjuvanted versus non-adjuvanted
42 results in 0.0807 seconds.
-
Giuseppe started a topic The Lancet Infect Dis. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trialin VaccinesThe Lancet Infect Dis. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial
[Source: The Lancet Infectious Diseases, full text: (LINK). Abstract, edited.]
-
Giuseppe started a topic Vaccine. An early (3-6 weeks) active surveillance study to assess the safety of pandemic influenza vaccine Focetria(?) in a province of Emilia-Romagna region, Italy - Part one.in VaccinesVaccine. An early (3-6 weeks) active surveillance study to assess the safety of pandemic influenza vaccine Focetria(?) in a province of Emilia-Romagna region, Italy - Part one.
[Source: US National Library of Medicine, full page: (LINK). Abstract, edited.]
Vaccine. 2012 Jul 2. [Epub ahead of print]...
An early (3-6 weeks) active surveillance study to assess the safety of pandemic influenza vaccine -
Giuseppe started a topic PLoS ONE. Estimation of the Health Impact and Cost-Effectiveness of Influenza Vaccination with Enhanced Effectiveness in Canadain VaccinesPLoS ONE. Estimation of the Health Impact and Cost-Effectiveness of Influenza Vaccination with Enhanced Effectiveness in Canada
[Source: PLoS ONE, full text: (LINK). Abstract, edited.]
Estimation of the Health Impact and Cost-Effectiveness of Influenza Vaccination with Enhanced Effectiveness in Canada...
by David N. Fisman, Ashleigh R. Tuite -
Giuseppe started a topic PLoS ONE. Effectiveness of the AS03-Adjuvanted Vaccine against Pandemic Influenza Virus A/(H1N1) 2009 ? A Comparison of Two Methods; Germany, 2009/10in VaccinesPLoS ONE. Effectiveness of the AS03-Adjuvanted Vaccine against Pandemic Influenza Virus A/(H1N1) 2009 ? A Comparison of Two Methods; Germany, 2009/10
[Source: PLoS ONE, full text: (LINK). Abstract, edited.]
Effectiveness of the AS03-Adjuvanted Vaccine against Pandemic Influenza Virus A/(H1N1) 2009 ? A Comparison of Two Methods; Germany, 2009/10...
Helmut Uphoff<SUP>1</SUP><SUP>*</SUP>, -
Giuseppe started a topic Proc Natl Acad Sci USA. Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59in VaccinesProc Natl Acad Sci USA. Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59
Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59 (PNAS, abstract, edited)
[Source: Proc Natl Acad Sci USA, full text: <cite cite="htt... -
Giuseppe started a topic Proc Natl Acad Sci USA. IFN-γ produced by CD8 T cells induces T-bet?dependent and ?independent class switching in B cells in responses to alum-precipitated protein vaccinein ImmunityProc Natl Acad Sci USA. IFN-γ produced by CD8 T cells induces T-bet?dependent and ?independent class switching in B cells in responses to alum-precipitated protein vaccine
IFN-γ produced by CD8 T cells induces T-bet?dependent and ?independent class switching in B cells in responses to alum-precipitated protein vaccine (PNAS, abstract, edited)
[Source: PNAS, <cite cite="http://www.pna... -
Giuseppe started a topic Vaccine. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates.in VaccinesVaccine. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates.
[Source: US National Library of Medicine (LINK). Edited.]
Vaccine. 2010 Apr 28. [Epub ahead of print]
Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines... -
Giuseppe started a topic Vaccine. Nasal mucosal administration of chitin microparticles boosts innate immunity against influenza A virus in the local pulmonary tissue.in VaccinesVaccine. Nasal mucosal administration of chitin microparticles boosts innate immunity against influenza A virus in the local pulmonary tissue.
[Source: US National Library of Medicine (LINK). Edited.]
Vaccine. 2010 Apr 27. [Epub ahead of print]
Nasal mucosal administration of chitin microparticles boosts innate immunity against influenza A virus in the local pulmonary... -
Giuseppe started a topic Vaccine. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.in VaccinesVaccine. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.
-
Giuseppe started a topic Vaccine. Production of H5N1 (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations.in VaccinesVaccine. Production of H5N1 (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations.
-
Giuseppe started a topic Vaccine. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03(A)-adjuvant: Preliminary report of an observer-blind, randomized trial.in VaccinesVaccine. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03(A)-adjuvant: Preliminary report of an observer-blind, randomized trial.
Vaccine. 2009 Dec 21. [Epub ahead of print]
Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03(A)-adjuvant: Preliminary report of an observer-blind, randomized trial.
... -
Ann Intern Med. Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic.
Ann Intern Med. 2009 Dec 15;151(12):840-53.
Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic.
Khazeni N, Hutton DW, Garber AM, Owens... -
Giuseppe started a topic N Engl J Med. Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccinein VaccinesN Engl J Med. Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine
Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine (N Engl J Med., abstract, edited)
Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine...
Tristan W. Clark, M.R.C.P., Manish Pareek, M.R.C.P., Katja -
N Engl J Med. A Novel Influenza A (H1N1) Vaccine in Various Age Groups
A Novel Influenza A (H1N1) Vaccine in Various Age Groups (N Engl J Med., abstract, edited)
A Novel Influenza A (H1N1) Vaccine in Various Age Groups...
Feng-Cai Zhu, M.D., Hua Wang, M.D., Han-Hua Fang, M.D., Jian Guo Yang, M.D., Xiao -
Giuseppe started a topic Vaccine development: experience from H5N1 to pandemic (H1N1) 2009 (WHO, presentation)in WHO (OMS)Vaccine development: experience from H5N1 to pandemic (H1N1) 2009 (WHO, presentation)
Source Full PDF Document: Marie-Paule Kieny - Vaccine development: experience from H5N1 to pandemic (H1N1) 2009 [pdf 1.26Mb]